PMEF
COGT icon

Point72 Middle East FZE’s Cogent Biosciences COGT Stock Holding History

Point72 Middle East FZE’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,201
Closed -$107K – 287
2023
Q4 		$107K Buy
+18,201
New +$139K ﹤0.01% 1177

Other funds holding COGT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Point72 Middle East FZE's COGT Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Cogent Biosciences (COGT) in Q1 2024, closing a stake of 18,201 shares — an estimated $107K sold.

Point72 Middle East FZE first reported a position in COGT in Q4 2023 and held it in 1 quarter. The position peaked at $107K in Q4 2023. 146 funds tracked by Wall St. Rank hold COGT as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Cogent Biosciences position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 18,201 Cogent Biosciences shares in Q1 2024, an estimated $107K.
  • Point72 Middle East FZE first reported a position in Cogent Biosciences in Q4 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Cogent Biosciences position peaked at $107K in Q4 2023.
  • 146 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.